In addition to the members of our Honorary Editorial Board, we would like to thank the following individuals, who acted as referees for articles in Drugs in R&D in 2012:

C646 in vivo Albert Adell, Spain Ali Alikhan, USA Robert J. Amato, USA Soo Kyung Bae, Republic of Korea Luis Bahamondes, Brazil Bernard check details Bannwarth, France Marcelo C. Bertolami, Brazil Joseph M. Blondeau, Canada Nichola Boyle, Australia Peter Bramlage, Germany Yong Chen, USA Victor Chuang, Australia Daniel F. Connor, USA Gilberto De Nucci, Brazil Sheila A. Doggrell, Australia Santiago Ewig, Germany David N. Franz, USA David J. Greenblatt, USA Ganesh V. Halade, USA Sanjeev Handa, India Klaas A. Hartholt, the Netherlands Daniel E. Hilleman, USA Gabor Hollo, Hungary Li Huafang, China Atsuko A. Inoue, Japan Makoto Ishikawa, Japan Hartmut Jaeschke, USA Joetta M. Juenke, USA Menelaos Karanikolas, Greece Kiyoshi Kikuchi, Japan Gideon Koren, Canada Paul A. Lapchak, USA Leonard Liebes, USA Charles L. Loprinzi, USA Gianluca Manni, Italy Robert Mathie, UK Andrew J. McLachlan, Australia Andrei V. Medvedovici, Romania Marco Montillo, Italy F. Marcel Musteata, USA Samar Muwakkit, Lebanon Taizen Nakase, Japan Hiroaki Naritomi, Japan Michinori Ogura, Japan Muge G. Ozden, Turkey Girolamo Pelaia, Italy Rita Pichardo, USA Charalampos Pierrakos, Belgium Simon W. Rabkin, Canada Alex Rawlinson, UK Claire Relton, UK James L. Roerig,

USA Menachem Rottem, Israel NVP-BSK805 in vivo Brian B.H. Rowe, Canada Barry Rumack, USA A. Oliver Sartor, USA Bancha Satirapoj, Thailand Rashmi R. Shah, UK Manuel Sosa, Spain Carlos Sostres, Spain Motohiro Tamiya, Japan Joel Tarning, Thailand Michael E. Thase, USA Sadao Tokimasa, Japan Chaitra S. Ujjani, USA Giuseppe Visani, Italy Mari Wataya-Kaneda, Japan Ping

Wei, China Paul Welsh, UK William N. William Jr., USA Johannes Wohlrab, Germany Cory Yamashita, Canada Takashi Yamashita, USA MYO10 Abdel N. Zaid, Palestinian Territory Xiangjian Zhang, China Yan Zhang, USA We look forward to your continued support of the journal in 2013 and to bringing you first-class content from around the globe. Best wishes from the staff of Drugs in R&D and all at Adis Publications.”
“Tuberous sclerosis complex (TSC) is an autosomal-dominant genetic disorder characterized by the formation of benign tumors in multiple organ systems. Facial angiofibromas appear as red or pink papules over the central face, especially on the nasolabial folds, cheeks, and chin,[1] in people with TSC. Lesions arise in early childhood and are present in up to 80% of TSC patients.[1,2] In some patients, the lesions become confluent and can result in severe disfigurement. Although multiple treatments have been developed to alleviate the appearance of facial angiofibromas – curettage, cryosurgery, chemical peels, dermabrasion, shave excisions, and laser therapy[3–8] – these are uncomfortable and need to be repeated at periodic intervals to treat recurrence.